A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 336
- 试验地点
- 15
- 主要终点
- Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
研究概览
简要总结
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.
Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.
Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.
Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study.
Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity.
As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must be ≥18 years of age and able to provide written informed consent
- •Diagnosis of the following:
- •o MUM: Uveal melanoma with histological or cytological confirmed metastatic disease. Metastatic disease may be treatment naïve or have progressed on or after most recent therapy. If the most recent therapy was an immune-oncology agent, PD must be confirmed.
- •- If a patient is treatment naïve and human leukocyte antigen (HLA)-A*02:01 positive***, documentation is required to provide rationale why treatment with tebentafusp is not the ideal firstline treatment approach or of the patient's intolerance to tebentafusp.
- •***To be enrolled in the HLA-A*02:01 positive cohort, HLA status must be documented by test results from a CAP/CLIA-certified laboratory.
- •Measurable disease per RECIST v1.1
- •Eastern Cooperative Oncology Group ≤1 and expected life expectancy of > 3 months
- •Adequate organ function at screening
- •Adequate contraceptive measures for non-sterilized male and female patients of childbearing potential
- •Crizotinib Combination Additional Inclusion Criteria:
- •Prior chemotherapy other therapies as applicable or major surgeries must have been completed at least 4 weeks prior to initiation of crizotinib
- •Patients with preexisting peripheral neuropathy can be included if it is Grade 1 or lower, prior to initiation of crizotinib Biopsy-eligible patients
- •Accessible lesion(s) that permit a total of at least two biopsies without unacceptable risk of a significant procedural complication.
排除标准
- •Previous treatment with a PKC inhibitor
- •Known MSI-H/dMMR tumors who have not previously received immune checkpoint inhibitors
- •Known symptomatic brain metastases
- •Adverse events from prior anti-cancer therapy that have not resolved
- •Known acquired immunodeficiency syndrome (AIDS)-related illness, hepatitis B virus, or hepatitis C virus
- •Active infection requiring ongoing therapy
- •Recent surgery or radiotherapy
- •Prior gastrectomy or upper bowel removal or any other gastrointestinal disorder or defect
- •Females who are pregnant or breastfeeding
- •Impaired cardiac function
- •Treatment with prohibited medications that cannot be discontinued prior to study entry
- •For patients receiving IDE196 powder-in-capsule (PIC) formulation or crizotinib, allergy to mammalian meat products and gelatin
- •Crizotinib Combination Additional Exclusion Criteria:
- •Prior therapy directly targeting ALK, MET, or ROS1
- •Spinal cord compression
- •History of pneumonitis or interstitial lung disease
- •History of syncope
- •History of thromboembolic or cerebrovascular events ≤12 weeks prior to first dose of study treatment
- •PK Substudy (optional) with Pravastatin Additional Exclusion Criteria:
- •Taken any dose of statin or inhibitor of organic anion transporting polypeptide within 7 days prior to enrollment in the study and cannot refrain from them through C2D1
- •Taken drugs that interfere with the absorption, metabolism, or elimination of pravastatin
- •Any contraindication associated to the use of statins or hypersensitivity component of pravastatin
- •Active liver disease
- •DDI Cocktail Substudy Additional Exclusion Criteria:
- •Treatment with bupropion, repaglinide, flurbiprofen, omeprazole, esomeprazole, midazolam, and dabigatran etexilate within 7 days prior to Cycle 1 Day -
- •Intake of vitamin supplements containing Vitamin B6 (pyridoxine), grapefruit/grapefruit juice, or Seville orange juice within 7 days prior to Cycle 1 Day -
- •Intake of any strong or moderate inhibitor of CYP2B6, CYP2CI, CYP2C9, CYP2C10 and OAT3 is prohibited within 7 days or within 5 half-lives, whichever is longer, of Cycle 1 Day -
- •Moderate and strong inhibitors of CYP2A4/5 or P-gp are prohibited within 7 days, or within 5 half-lives, whichever is longer, of Cycle 1 Day -
- •Intake of strong or moderate inducers of CYP3A4/5, CYP2B6, CYP2C9, CYP2C19, or OAT3 is prohibited during 15 days, or 5 half-lives, whichever is longer, prior to Cycle 1 Day -1.
研究组 & 干预措施
Dose Escalation Monotherapy (Enrollment Complete)
IDE196 dosed orally, twice daily (BID) for each 28-day cycle
干预措施: IDE196 (Drug)
Dose Expansion Monotherapy (Enrollment Complete)
RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations or PRKC fusions (cutaneous melanoma, CRC, other solid tumors)
干预措施: IDE196 (Drug)
Dose Escalation Binimetinib Combination (Enrollment Complete)
IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Binimetinib dosed orally, twice daily (BID) for each 28-day cycle
干预措施: IDE196 (Drug)
Dose Escalation Binimetinib Combination (Enrollment Complete)
IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Binimetinib dosed orally, twice daily (BID) for each 28-day cycle
干预措施: Binimetinib (Drug)
Dose Expansion Binimetinib Combination (Enrollment Complete)
RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)
干预措施: IDE196 (Drug)
Dose Expansion Binimetinib Combination (Enrollment Complete)
RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)
干预措施: Binimetinib (Drug)
Dose Escalation Crizotinib Combination (Enrollment Complete)
IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle
干预措施: IDE196 (Drug)
Dose Escalation Crizotinib Combination (Enrollment Complete)
IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle
干预措施: Crizotinib (Drug)
Dose Expansion Crizotinib Combination (Enrolling)
MUM patients (previously treated or treatment naive) with human leukocyte antigen (HLA)-A*02:01 positive status.
Includes a nested PK sub-study with Pravastatin (~22 participants) to evaluate the impact of pravastatin PK profiles after continuous dosing of IDE196.
Includes a nested PK Cocktail DDI sub-study (~15 participants) to evaluate the impact on the PK of bupripion, repaglinide, flurbiprofen, omeprazole, midazolam, dabigatran etexilate, and the exposures of the OAT3 biomarker PDA by IDE196 in combination with crizotinib.
干预措施: IDE196 (Drug)
Dose Expansion Crizotinib Combination (Enrolling)
MUM patients (previously treated or treatment naive) with human leukocyte antigen (HLA)-A*02:01 positive status.
Includes a nested PK sub-study with Pravastatin (~22 participants) to evaluate the impact of pravastatin PK profiles after continuous dosing of IDE196.
Includes a nested PK Cocktail DDI sub-study (~15 participants) to evaluate the impact on the PK of bupripion, repaglinide, flurbiprofen, omeprazole, midazolam, dabigatran etexilate, and the exposures of the OAT3 biomarker PDA by IDE196 in combination with crizotinib.
干预措施: Crizotinib (Drug)
Dose Optimization Crizotinib Combination (Enrollment Complete)
IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle
干预措施: IDE196 (Drug)
Dose Optimization Crizotinib Combination (Enrollment Complete)
IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle
干预措施: Crizotinib (Drug)
Crizotinib Monotherapy with Crossover to Combination (Enrollment Complete)
Crizotinib dosed orally, twice daily (BID) for each 28-day cycle until disease progression then IDE196 added and dosed orally, twice daily (BID) for each 28-day cycle
干预措施: IDE196 (Drug)
Crizotinib Monotherapy with Crossover to Combination (Enrollment Complete)
Crizotinib dosed orally, twice daily (BID) for each 28-day cycle until disease progression then IDE196 added and dosed orally, twice daily (BID) for each 28-day cycle
干预措施: Crizotinib (Drug)
结局指标
主要结局
Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
时间窗: Approx. 6 months
Determine RP2D of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Maximum Tolerated Dose (MTD)
时间窗: 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Determine MTD of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Plasma Concentrations of Binimetinib administered in combination with IDE196
时间窗: Approx. 6 months
Pharmacokinetics of Binimetinib in combination with IDE196
Plasma Concentrations of Crizotinib administered in combination with IDE196
时间窗: Approx. 6 months
Pharmacokinetics of Crizotinib in combination with IDE196
Dose-limiting Toxicity (DLT)
时间窗: 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Determine DLT of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Plasma Concentrations of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
时间窗: Approx. 6 months
Pharmacokinetics of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Incidence of Adverse Events
时间窗: Approx. 8 months
Safety and tolerability of IDE196 either as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment
时间窗: Approx. 8 months
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) criteria
Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment
时间窗: Approx. 8 months
RECIST v1.1
Phramacokinetic parameters of bupropion, hydroxybupropion, repaglinide, flurbiprofen, omeprazole, midazolam, total dabigatran, and the exposures of pyridoxic acid by IDE196 monotherapy and IDE196 in combination with Crizotinib
时间窗: Approx. 8 months
PK parameters of drug cocktail
次要结局
- Progression Free Survival (PFS) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment(Approx. 18 months)
- Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts and by prior treatment status (pretreated or treatment naive) by Investigator response assessment(Approx. 18 months)
- Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by prior treatment status (pretreated or treatment naive) by Investigator response assessment(Approx. 18 months)
- Disease Control Rate (DCR) by Investigator(Approx. 18 months)